Literature DB >> 23754791

Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis.

Prakash Radhakrishnan1, Paul M Grandgenett, Ashley M Mohr, Stephanie K Bunt, Fang Yu, Sanjib Chowdhury, Michael A Hollingsworth.   

Abstract

Core 3-derived glycans, a major type of O-glycan expressed by normal epithelial cells of the gastrointestinal tract, are downregulated during malignancy because of loss of expression of functional β3-N-acetylglucosaminyltransferase-6 (core 3 synthase). We investigated the expression of core 3 synthase in normal pancreas and pancreatic cancer and evaluated the biological effects of re-expressing core 3 synthase in pancreatic cancer cells that had lost expression. We determined that pancreatic tumors and tumor cell lines have lost expression of core 3 synthase. Therefore, we re-expressed core 3 synthase in human pancreatic cancer cells (Capan-2 and FG) to investigate the contribution of core 3 glycans to malignant progression. Pancreatic cancer cells expressing core 3 synthase showed reduced in vitro cell proliferation, migration and invasion compared to vector control cells. Expression of core 3 O-glycans induced altered expression of β1 integrin, decreased activation of focal adhesion kinase, led to the downregulation of expression of several genes including REG1α and FGFR3 and altered lamellipodia formation. The addition of a GlcNAc residue by core 3 synthase leads to the extension of the tumor-associated Tn structure on MUC1. Orthotopic injection of FG cells expressing core 3 synthase into the pancreas of nude mice produced significantly smaller tumors and decreased metastasis to the surrounding tissues compared to vector control FG cells. These findings indicate that expression of core 3-derived O-glycans in pancreatic cancer cells suppresses tumor growth and metastasis through modulation of glycosylation of mucins and other cell surface and extracellular matrix proteins.
Copyright © 2013 UICC.

Entities:  

Keywords:  MUC1; O-glycan; core 3 synthase; pancreatic cancer; α2β1 integrin

Mesh:

Substances:

Year:  2013        PMID: 23754791      PMCID: PMC3873636          DOI: 10.1002/ijc.28322

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  42 in total

Review 1.  Mucins in cancer: protection and control of the cell surface.

Authors:  Michael A Hollingsworth; Benjamin J Swanson
Journal:  Nat Rev Cancer       Date:  2004-01       Impact factor: 60.716

2.  Molecular cloning and characterization of a novel UDP-GlcNAc:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans.

Authors:  Toshie Iwai; Niro Inaba; Andreas Naundorf; Yan Zhang; Masanori Gotoh; Hiroko Iwasaki; Takashi Kudo; Akira Togayachi; Yasuko Ishizuka; Hiroshi Nakanishi; Hisashi Narimatsu
Journal:  J Biol Chem       Date:  2002-01-30       Impact factor: 5.157

3.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state.

Authors:  Y Altschuler; C L Kinlough; P A Poland; J B Bruns; G Apodaca; O A Weisz; R P Hughey
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

4.  Tenascin C expression is upregulated in pancreatic cancer and correlates with differentiation.

Authors:  A Juuti; S Nordling; J Louhimo; J Lundin; C Haglund
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

5.  Clinicopathological significance of core 2 beta1,6-N-acetylglucosaminyltransferase messenger RNA expressed in the pulmonary adenocarcinoma determined by in situ hybridization.

Authors:  E Machida; J Nakayama; J Amano; M Fukuda
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  AKAP12/Gravin is inactivated by epigenetic mechanism in human gastric carcinoma and shows growth suppressor activity.

Authors:  Moon-Chang Choi; Hyun-Soon Jong; Tai Young Kim; Sang-Hyun Song; Dong Soon Lee; Jung Weon Lee; Tae-You Kim; Noe Kyeong Kim; Yung-Jue Bang
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

7.  Expression of sialyl-Tn epitopes on beta1 integrin alters epithelial cell phenotype, proliferation and haptotaxis.

Authors:  Monique Clément; Jézabel Rocher; Gervaise Loirand; Jacques Le Pendu
Journal:  J Cell Sci       Date:  2004-09-21       Impact factor: 5.285

8.  Sialylated core 1 based O-linked glycans enhance the growth rate of mammary carcinoma cells in MUC1 transgenic mice.

Authors:  Arron Mungul; Lucienne Cooper; Inka Brockhausen; Kenneth Ryder; Ulla Mandel; Henrik Clausen; Aurelia Rughetti; David W Miles; Joyce Taylor-Papadimitriou; Joy M Burchell
Journal:  Int J Oncol       Date:  2004-10       Impact factor: 5.650

9.  Increased UDP-GlcNAc:Gal beta 1-3GaLNAc-R (GlcNAc to GaLNAc) beta-1, 6-N-acetylglucosaminyltransferase activity in metastatic murine tumor cell lines. Control of polylactosamine synthesis.

Authors:  S Yousefi; E Higgins; Z Daoling; A Pollex-Krüger; O Hindsgaul; J W Dennis
Journal:  J Biol Chem       Date:  1991-01-25       Impact factor: 5.157

10.  BTG1, a member of a new family of antiproliferative genes.

Authors:  J P Rouault; R Rimokh; C Tessa; G Paranhos; M Ffrench; L Duret; M Garoccio; D Germain; J Samarut; J P Magaud
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

View more
  17 in total

1.  Immature truncated O-glycophenotype of cancer directly induces oncogenic features.

Authors:  Prakash Radhakrishnan; Sally Dabelsteen; Frey Brus Madsen; Chiara Francavilla; Katharina L Kopp; Catharina Steentoft; Sergey Y Vakhrushev; Jesper V Olsen; Lars Hansen; Eric P Bennett; Anders Woetmann; Guangliang Yin; Longyun Chen; Haiyan Song; Mads Bak; Ryan A Hlady; Staci L Peters; Rene Opavsky; Christenze Thode; Klaus Qvortrup; Katrine T-B G Schjoldager; Henrik Clausen; Michael A Hollingsworth; Hans H Wandall
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-12       Impact factor: 11.205

2.  Core 2 Mucin-Type O-Glycan Is Related to EPEC and EHEC O157:H7 Adherence to Human Colon Carcinoma HT-29 Epithelial Cells.

Authors:  Jun Ye; Lili Song; Yun Liu; Qiong Pan; Xiaoli Zhong; Shanshan Li; Yangyang Shang; Yin Tian; Yonghong He; Lei Chen; Wensheng Chen; Zhihong Peng; Rongquan Wang
Journal:  Dig Dis Sci       Date:  2015-02-21       Impact factor: 3.199

3.  Molecular Pathways: Mucins and Drug Delivery in Cancer.

Authors:  Chinthalapally V Rao; Naveena B Janakiram; Altaf Mohammed
Journal:  Clin Cancer Res       Date:  2016-12-30       Impact factor: 12.531

4.  Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity.

Authors:  J Ye; X Wei; Y Shang; Q Pan; M Yang; Y Tian; Y He; Z Peng; L Chen; W Chen; R Wang
Journal:  Oncogene       Date:  2017-07-24       Impact factor: 9.867

5.  Isoforms of MUC16 activate oncogenic signaling through EGF receptors to enhance the progression of pancreatic cancer.

Authors:  Divya Thomas; Satish Sagar; Xiang Liu; Hye-Rim Lee; James A Grunkemeyer; Paul M Grandgenett; Thomas Caffrey; Kelly A O'Connell; Benjamin Swanson; Lara Marcos-Silva; Catharina Steentoft; Hans H Wandall; Hans Carlo Maurer; Xianlu Laura Peng; Jen Jen Yeh; Fang Qiu; Fang Yu; Ragupathy Madiyalakan; Kenneth P Olive; Ulla Mandel; Henrik Clausen; Michael A Hollingsworth; Prakash Radhakrishnan
Journal:  Mol Ther       Date:  2020-12-25       Impact factor: 11.454

6.  MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.

Authors:  Satish Sagar; Pramila D Leiphrakpam; Divya Thomas; Kyle L McAndrews; Thomas C Caffrey; Benjamin J Swanson; Henrik Clausen; Hans H Wandall; Michael A Hollingsworth; Prakash Radhakrishnan
Journal:  Cancer Lett       Date:  2021-01-22       Impact factor: 8.679

Review 7.  Mucins as anti-cancer targets: perspectives of the glycobiologist.

Authors:  Inka Brockhausen; Jacob Melamed
Journal:  Glycoconj J       Date:  2021-03-11       Impact factor: 2.916

8.  Loss of E-cadherin and epithelial to mesenchymal transition is not required for cell motility in tissues or for metastasis.

Authors:  Xiang Liu; Huocong Huang; Neeley Remmers; Michael A Hollingsworth
Journal:  Tissue Barriers       Date:  2014-08-08

Review 9.  Altered glycosylation in cancer: A promising target for biomarkers and therapeutics.

Authors:  Divya Thomas; Ashok Kumar Rathinavel; Prakash Radhakrishnan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-11-04       Impact factor: 10.680

Review 10.  Altered tumor-cell glycosylation promotes metastasis.

Authors:  Irina Häuselmann; Lubor Borsig
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.